REG - Tate & Lyle PLC - Acquisition

Tate & LyleAnnouncement

09/06/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220609:nRSI2932Oa&default-theme=true

RNS Number : 2932O  Tate & Lyle PLC  09 June 2022

FOR IMMEDIATE RELEASE

 

 

Tate & Lyle completes acquisition of dietary fibre business in China

 

London, UK, 9 June 2022 - Tate & Lyle PLC (Tate & Lyle), a leading
global provider of food and beverage ingredients and solutions, announces that
it has today completed the acquisition of Quantum Hi-Tech (Guangdong)
Biological Co., Ltd (Quantum), a leading prebiotic dietary fibre business
located in China. The signing of a conditional agreement for this acquisition
was announced on 31 March 2022.

 

Nick Hampton, Chief Executive of Tate & Lyle, said:

"This acquisition significantly strengthens our fortification platform and our
position as a leading global player in dietary fibres, while extending our
presence in China and Asia.  FOS and GOS fibres are highly complementary to
our existing fibre portfolio and will allow us to offer a broader range of
solutions to our customers across key markets.

 

We are delighted to welcome our new colleagues from Quantum to Tate &
Lyle.  Quantum is a great fit with our growth strategy and our purpose of
Transforming Lives through the Science of Food, giving us more opportunities
to improve gut health and provide fibre fortification for consumers across the
world."

 

ENDS

Notes to editors

1.  FOS are fructo-oligosaccharides and GOS are galacto-oligosaccharides,

2.  Read the initial announcement press release: Tate & Lyle to acquire
leading dietary fibre business in China
(https://www.tateandlyle.com/news/tate-lyle-acquire-leading-dietary-fibre-business-china)
- 31 March 2022

 

For more information contact Tate & Lyle PLC

Investor Relations:

Christopher Marsh, VP, Investor Relations

Mobile: +44 (0) 7796 192 688

 

Media:

Nick Hasell, FTI Consulting

Mobile: +44 (0) 7825 523 383

 

About Tate & Lyle

 

Tate & Lyle is a leading global provider of food and beverage ingredients
and solutions. Supported by our 160-year history of ingredient innovation, we
partner with customers to provide consumers with healthier and tastier choices
when they eat and drink. We are proud that millions of people around the world
consume products containing our ingredients every day.

 

Through our expertise in sweetening, mouthfeel and fortification, we develop
solutions which reduce sugar, calories and fat, add fibre, and provide texture
and stability in categories including beverages, dairy, bakery, soups, sauces
and dressings.

 

We have more than 3,000 employees working in around 60 locations across 30
countries. Tate & Lyle's purpose is Transforming Lives Through the Science
of Food and through our purpose we believe we can successfully grow our
business and have a positive impact on society. We live our purpose in three
ways, by supporting healthy living, building thriving communities and caring
for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol
TATE.L. American Depositary Receipts trade under TATYY. In the year ended 31
March 2021, Tate & Lyle's revenue from continuing operations totaled £1.2
billion. For more information, please visit https://www.tateandlyle.com or
follow Tate & Lyle on Twitter, LinkedIn or Facebook.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQGLGDLDGGDGDC